Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly and Rigel Pharmaceuticals have announced a global exclusive license agreement to co-develop Rigel's RIPK1 inhibitor, R552, targeting autoimmune and inflammatory diseases. Lilly will make an upfront payment of $125 million and could pay up to $835 million in milestone payments, plus royalties. R552 has completed Phase 1 trials and will enter Phase 2 trials in 2021. Lilly will lead clinical development and commercialization efforts, while Rigel retains co-commercialization rights in the U.S. This partnership seeks to advance treatments in both immune and CNS disease areas.

Eli Lilly and Company's tirzepatide demonstrated significant reductions in A1C levels and body weight in phase 3 clinical trials SURPASS-3 and SURPASS-5 for adult patients with type 2 diabetes. After 52 weeks and 40 weeks, respectively, significant endpoints were achieved, with the highest dose (15 mg) lowering A1C by up to 2.59% and body weight by 12.9 kg. Up to 62.4% of participants achieved A1C levels below 5.7%. The safety profile was comparable to existing GLP-1 receptor agonists, with gastrointestinal issues being the most frequent side effects. Results will be presented at upcoming scientific sessions.

On February 16, 2021, Eli Lilly and Company (NYSE: LLY) appointed Kimberly H. Johnson to its board of directors. Johnson, currently the executive vice president and COO of Fannie Mae, will contribute her expertise in technology, governance, and global risk management. She holds degrees in Economics from Princeton University and an MBA from Columbia Business School. Her addition is expected to enhance the board's capabilities, particularly in financial strategy and oversight.

Eli Lilly and Company (NYSE:LLY) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. Senior Vice President Ilya Yuffa will engage in a fireside chat at 1:40 p.m. ET. A live audio webcast will be accessible on Lilly's investor website, with a replay available for 90 days. Founded over a century ago, Lilly remains committed to producing high-quality medicines and enhancing disease management globally.

The U.S. FDA has granted Emergency Use Authorization (EUA) for Eli Lilly's investigational therapy combining bamlanivimab (700 mg) and etesevimab (1400 mg) for treating mild to moderate COVID-19 in high-risk patients aged 12 and older. Administered together via intravenous infusion, this therapy aims to reduce hospitalization and death risk by 70%, based on Phase 3 data from the BLAZE-1 trial. The EUA allows a significant reduction in infusion times and is part of Lilly's ongoing commitment to combat COVID-19. Manufacturing plans include up to 1 million doses by mid-2021.

Eli Lilly has appointed Anat Ashkenazi as chief financial officer, succeeding Josh Smiley, who resigned due to allegations of inappropriate conduct. An external investigation confirmed poor judgment on Smiley's part, although his actions were not linked to financial matters. Ashkenazi, with nearly 20 years at Lilly, previously served as CFO of Lilly Research Laboratories and is expected to advance the company's strategy and shareholder value. CEO David A. Ricks expressed confidence in Ashkenazi's leadership amid Lilly's strong financial performance and promising pipeline.

Eli Lilly and Company (NYSE: LLY) will hold a webcast on March 15, 2021 at 10:30 a.m. Eastern Time to discuss its Alzheimer's disease program, including results from the Phase 2 TRAILBLAZER-ALZ study for donanemab. This information will be shared at the 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD). Both investors and the public can access the live webcast via the company's website, with a replay available afterward.

Eli Lilly and Company (NYSE: LLY) will attend the Guggenheim Healthcare Talks 2021 Oncology Day on February 12, 2021. Senior VP Anne White and CEO Jacob Van Naarden will host a fireside chat at 11:00 a.m. ET. Investors can access a live audio webcast on Lilly's Investor website and a replay will be available for 90 days. Eli Lilly is dedicated to improving global health through innovative medicine and community engagement.

Eli Lilly and Company (NYSE: LLY) has partnered with local health systems in Indiana to establish dedicated infusion centers for COVID-19 treatments. These centers will provide access to authorized neutralizing antibody therapies for high-risk patients. The initiative includes new locations serving southern Indiana and has already treated over 1,700 patients. Lilly aims to enhance healthcare delivery by sharing insights with stakeholders and encourages other health systems to create similar facilities. The company's ongoing efforts in COVID-19 treatment are part of its broader commitment to address the pandemic.